Sequent Medical has been granted a new patent from the US Patent and Trademark Office covering many versions of Sequent’s Web aneurysm embolisation system.
Web is a braided implant that includes composite drawn filled tube wires, ie. an external nitinol tube and a highly radiopaque material disposed within the tube. The devices utilise this technology for enhanced visualisation while preserving desired mechanical properties. Web is braided from numerous wires, which in some cases are less than one-quarter of the diameter of a human hair.
The company has previously developed and introduced enhanced visualisation versions of Web in single-layer Web SL and SLS configurations in Europe. In the USA, enrolment in an investigational device exemption clinical study called WEB-IT is underway, with WEB EV designs now being implanted in the study.
“Improving the visualisation of Web proved to be a significant engineering challenge,” said Tom Wilder, president and chief executive officer. “Enhanced visualisation technology is the latest demonstration of Sequent’s robust innovation capability, and further extends our leadership of the intrasaccular flow disruption category. The utility of Sequent’s proprietary technology extends beyond the neurovascular field, and has the potential to address a number of unmet clinical needs.”
